Drug guidance
Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer
1 September 2023
Condition
Breast
Cancer
Published on 17 Jul 2023
Last Updated on 01 Sep 2023
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended trastuzumab deruxtecan (T-DXd) for inclusion on the MOH List of Subsidised Drugs for treating human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic breast cancer after a prior anti-HER2-based regimen. The decision was based on the uncertain extent of clinical benefit and unfavourable cost-effectiveness of T-DXd at the price proposed by the company compared with alternative treatments.
Clinical indication, subsidy class and MediShield Life claim limit for T-DXd are provided in the Annex.